In addition, we predicted the sensitivity of common anti-cancer drugs on prognostic signature, including CCR5 (Fig. 6C), HMOX1 (Fig. 6D), CTSC (Fig. 6E), CD5 (Fig. 6F), BCL3 (Fig. 6G), CDH1 (Fig. 6H), TYROBP and CD38 (Fig. 6I). Here, BCL3 is linked to cancer.